View Item 

Show simple item record

Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?
dc.contributor.authorFerreira, João Pedro
dc.contributor.authorMentz, Robert J.
dc.contributor.authorPizard, Anne
dc.contributor.authorPitt, Bertram
dc.contributor.authorZannad, Faiez
dc.date.accessioned2017-10-05T18:17:51Z
dc.date.available2018-11-01T16:42:00Zen
dc.date.issued2017-08
dc.identifier.citationFerreira, João Pedro ; Mentz, Robert J.; Pizard, Anne; Pitt, Bertram; Zannad, Faiez (2017). "Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?." European Journal of Heart Failure 19(8): 974-986.
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.urihttps://hdl.handle.net/2027.42/138286
dc.description.abstractThe aim of personalized medicine is to offer a tailored approach to each patient in order to provide the most effective therapy, while reducing risks and side effects. The use of mineralocorticoid receptor antagonists (MRAs) has demonstrated major benefits in heart failure with reduced ejection fraction (HFrEF), results with challenging inconsistencies in heart failure with preserved ejection fraction (HFpEF), and ‘neutral’ preliminary results in acute heart failure. Data derived from landmark trials are generally applied in a ‘one size fits all’ manner and the development and implementation of more personalized MRA management would offer the potential to improve outcomes and reduce side effects. However, the personalization of pharmacotherapy regimens remains poorly defined in the cardiovascular field (in light of current knowledge) and until further trials targeting specific subpopulations have been conducted, MRAs should be provided to the great majority of HFrEF patients in the absence of contraindication. Spironolactone should be considered for symptomatic HFpEF patients with elevated natriuretic peptides. In the near future, trials should target HFrEF patients using exclusion criteria sourced from landmark trials (e.g. severe renal impairment), select more homogeneous HFpEF populations (e.g. with elevated BNP and structural abnormalities on echocardiography), and determine which patients are likely to benefit from MRAs (e.g. according to prespecified biomarkers).
dc.publisherJohn Wiley & Sons, Ltd
dc.subject.otherHeart failure
dc.subject.otherMineralocorticoid receptor antagonists
dc.subject.otherPersonalized medicine
dc.titleTailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138286/1/ejhf814_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138286/2/ejhf814.pdf
dc.identifier.doi10.1002/ejhf.814
dc.identifier.sourceEuropean Journal of Heart Failure
dc.identifier.citedreferenceCarillo S, Zhang Y, Fay R, Angioi M, Vincent J, Sutradhor SC, Ahmed A, Pitt B, Zannad F. Heart failure with systolic dysfunction complicating acute myocardial infarction – differential outcomes but similar eplerenone efficacy by ST‐segment or non‐ST‐segment elevation: a post hoc substudy of the EPHESUS trial. Arch Cardiovasc Dis 2014; 107: 149 – 157.
dc.identifier.citedreferenceChen Y, Wang H, Lu Y, Huang X, Liao Y, Bin J. Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta‐analysis of randomized clinical trials. BMC Med 2015; 13: 10.
dc.identifier.citedreferenceSolomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O’Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016; 37: 455 – 462.
dc.identifier.citedreferenceAdamopoulos C, Ahmed A, Fay R, Angioi M, Filippatos G, Vincent J, Pitt B, Zannad F. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Fail 2009; 11: 1099 – 1105.
dc.identifier.citedreferenceGirerd N, Collier T, Pocock S, Krum H, McMurray JJ, Swedberg K, van Veldhuisen DJ, Vincent J, Pitt B, Zannad F. Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS‐HF trial. Eur Heart J 2015; 36: 2310 – 2317.
dc.identifier.citedreferenceFerreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. Eur J Intern Med 2014; 25: 67 – 72.
dc.identifier.citedreferenceFerreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H. Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors. Clin Res Cardiol 2013; 102: 745 – 753.
dc.identifier.citedreferenceFerreira JP, Girerd N, Medeiros PB, Santos M, Carvalho HC, Bettencourt P, Kenizou D, Butler J, Zannad F, Rossignol P. Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. Clin Res Cardiol 2016; 105: 489 – 507.
dc.identifier.citedreferenceButler J, Hernandez AF, Anstrom KJ, Kalogeropoulos A, Redfield MM, Konstam MA, Tang WH, Felker GM, Shah MR, Braunwald E. Rationale and design of the ATHENA‐HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. JACC Heart Fail 2016; 4: 726 – 735.
dc.identifier.citedreferenceDelyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000; 57: 1408 – 1411.
dc.identifier.citedreferenceCeremuzynski L, Budaj A, Michorowski B. Single‐dose i.v. aldactone for congestive heart failure: a preliminary observation. Int J Clin Pharmacol Ther Toxicol 1983; 21: 417 – 421.
dc.identifier.citedreferenceMaron BA, Leopold JA. Aldosterone receptor antagonists: effective but often forgotten. Circulation 2010; 121: 934 – 939.
dc.identifier.citedreferencePitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ‐Schmidt H, Berman L, Weir MR. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 2015; 17: 1057 – 1065.
dc.identifier.citedreferenceAnker SD, Kosiborod M, Zannad F, Pina IL, McCullough PA, Filippatos G, van der Meer P, Ponikowski P, Rasmussen HS, Lavin PT, Singh B, Yang A, Deedwania P. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial. Eur J Heart Fail 2015; 17: 1050 – 1056.
dc.identifier.citedreferenceWeir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ‐Schmidt H, Berman L, Pitt B. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015; 372: 211 – 221.
dc.identifier.citedreferenceKosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014; 312: 2223 – 2233.
dc.identifier.citedreferenceGirerd N, Magne J, Rabilloud M, Charbonneau E, Mohamadi S, Pibarot P, Voisine P, Baillot R, Doyle D, Dumont E, Dagenais F, Mathieu P. The impact of complete revascularization on long‐term survival is strongly dependent on age. Ann Thorac Surg 2012; 94: 1166 – 1172.
dc.identifier.citedreferenceGirerd N, Rabilloud M, Duarte K, Roy P. Number needed to treat from absolute risk and incidence rate: how to make apples and oranges comparable? J Clin Epidemiol 2014; 67: 236 – 238.
dc.identifier.citedreferenceBerry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 2015; 313: 1619 – 1620.
dc.identifier.citedreferenceLedwidge M, Gallagher J, Conlon C, Tallon E, O’Connell E, Dawkins I, Watson C, O’Hanlon R, Bermingham M, Patle A, Badabhagni MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K. Natriuretic peptide‐based screening and collaborative care for heart failure: the STOP‐HF randomized trial. JAMA 2013; 310: 66 – 74.
dc.identifier.citedreferenceJacobs L, Thijs L, Jin Y, Zannad F, Mebazaa A, Rouet P, Pinet F, Bauters C, Pieske B, Tomaschitz A, Mamas M, Diez J, McDonald K, Cleland JG, Rocca HP, Heymans S, Latini R, Masson S, Sever P, Delles C, Pocock S, Collier T, Kuznetsova T, Staessen JA. Heart ‘omics’ in AGEing (HOMAGE): design, research objectives and characteristics of the common database. J Biomed Res 2014; 28: 349 – 359.
dc.identifier.citedreferenceKirchhof P, Sipido KR, Cowie MR, Eschenhagen T, Fox KA, Katus H, Schroeder S, Schunkert H, Priori S. The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J 2014; 35: 3250 – 3257.
dc.identifier.citedreferenceZannad F, Koenig W. Risk‐guided therapy: a first step to personalized medicine. Eur J Prev Cardiol 2012; 19 ( 2 Suppl.): 5 – 6.
dc.identifier.citedreferenceKasper EK, Gerstenblith G, Hefter G, Van Anden E, Brinker JA, Thiemann DR, Terrin M, Forman S, Gottlieb SH. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll Cardiol 2002; 39: 471 – 480.
dc.identifier.citedreferenceCurran‐Everett D, Milgrom H. Post‐hoc data analysis: benefits and limitations. Curr Opin Allergy Clin Immunol 2013; 13: 223 – 224.
dc.identifier.citedreferenceSaville BR, Berry SM. Efficiencies of platform clinical trials: a vision of the future. Clin Trials 2016; 13: 358 – 366.
dc.identifier.citedreferenceGirerd N, Zannad F, Rossignol P. Review of heart failure treatment in type 2 diabetes patients: it’s at least as effective as in non‐diabetic patients! Diabetes Metab 2015; 41: 446 – 455.
dc.identifier.citedreferenceFerreira JP, Coiro S, Girerd N. A systematic assessment of absolute treatment effect. Am J Cardiol 2015; 116: 829 – 831.
dc.identifier.citedreferenceCoiro S, Pedro Ferreira J, Ambrosio G, Zannad F, Girerd N. To the Editor – Diabetes and sudden death: let’s assess the absolute risk increase rather than the proportional risk from sudden cardiac death! Heart Rhythm 2015; 12:e138.
dc.identifier.citedreferencePitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709 – 717.
dc.identifier.citedreferenceZannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11 – 21.
dc.identifier.citedreferencePitt B, Williams G, Remme W, Martinez F, Lopez‐Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post‐AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001; 15: 79 – 87.
dc.identifier.citedreferenceVardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 2012; 60: 2082 – 2089.
dc.identifier.citedreferenceVardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD. Incidence, predictors, and outcomes related to hypo‐ and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 2014; 7: 573 – 579.
dc.identifier.citedreferenceVardeny O, Cavallari LH, Claggett B, Desai AS, Anand I, Rossignol P, Zannad F, Pitt B, Solomon SD. Race influences the safety and efficacy of spironolactone in severe heart failure. Circ Heart Fail 2013; 6: 970 – 976.
dc.identifier.citedreferenceMcNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Taylor AL, Cohn JN, Feldman AM, Worcel M. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A‐HeFT Trial. J Am Coll Cardiol 2006; 48: 1277 – 1282.
dc.identifier.citedreferenceBiolo A, Chao T, Duhaney TA, Kotlyar E, Allensworth‐Davies D, Loscalzo J, Sam F. Usefulness of the aldosterone synthase gene polymorphism C‐344‐T to predict cardiac remodeling in African‐Americans versus non‐African‐Americans with chronic systolic heart failure. Am J Cardiol 2007; 100: 285 – 290.
dc.identifier.citedreferenceParsa A, Kanetsky PA, Xiao R, Gupta J, Mitra N, Limou S, Xie D, Xu H, Anderson AH, Ojo A, Kusek JW, Lora CM, Hamm LL, He J, Sandholm N, Jeff J, Raj DE, Boger CA, Bottinger E, Salimi S, Parekh RS, Adler SG, Langefeld CD, Bowden DW, Groop PH, Forsblom C, Freedman BI, Lipkowitz M, Fox CS, Winkler CA, Feldman HI; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Genome‐wide association of CKD progression: the Chronic Renal Insufficiency Cohort Study. J Am Soc Nephrol 2017; 28: 923 – 934.
dc.identifier.citedreferenceZannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000; 102: 2700 – 2706.
dc.identifier.citedreferenceZannad F, Radauceanu A. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. Heart Fail Rev 2005; 10: 71 – 78.
dc.identifier.citedreferenceCooper LB, Hammill BG, Peterson ED, Pitt B, Maciejewski ML, Curtis LH, Hernandez AF. Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. JAMA 2015; 314: 1973 – 1975.
dc.identifier.citedreferencePaget MA, Chuang‐Stein C, Fletcher C, Reid C. Subgroup analyses of clinical effectiveness to support health technology assessments. Pharm Stat 2011; 10: 532 – 538.
dc.identifier.citedreferenceEschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS‐HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013; 62: 1585 – 1593.
dc.identifier.citedreferenceCollier TJ, Pocock SJ, McMurray JJ, Zannad F, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS‐HF trial. Eur Heart J 2013; 34: 2823 – 2829.
dc.identifier.citedreferenceSwedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, Vincent J, Pitt B. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS‐HF (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59: 1598 – 1603.
dc.identifier.citedreferenceRossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF). Circ Heart Fail 2014; 7: 51 – 58.
dc.identifier.citedreferenceCannon JA, Collier TJ, Shen L, Swedberg K, Krum H, van Veldhuisen DJ, Vincent J, Pocock SJ, Pitt B, Zannad F, McMurray JJ. Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS‐HF). Eur J Heart Fail 2015; 17: 707 – 716.
dc.identifier.citedreferenceChin KL, Collier TJ, Pitt B, McMurray JJ, Swedberg K, van Veldhuisen DJ, Pocock SJ, Vincent J, Turgonyi E, Zannad F, Krum H. Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS‐HF study. Eur J Heart Fail 2016; 18: 1175 – 1181.
dc.identifier.citedreferenceYoucef G, Olivier A, Nicot N, Muller A, Deng C, Labat C, Fay R, Rodriguez‐Gueant RM, Leroy C, Jaisser F, Zannad F, Lacolley P, Vallar L, Pizard A. Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats. Br J Pharmacol 2016; 173: 1805 – 1819.
dc.identifier.citedreferenceOlivier A, Pitt B, Girerd N, Lamiral Z, Machu JL, McMurray JJ, Swedberg K, van Veldhuisen DJ, Collier TJ, Pocock SJ, Rossignol P, Zannad F, Pizard A. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity: Insight from the EMPHASIS‐HF trial. Eur J Heart Fail 2017 Mar 16. doi: 10.1002/ejhf.792. [Epub ahead of print].
dc.identifier.citedreferenceGupta PP, Fonarow GC, Horwich TB. Obesity and the obesity paradox in heart failure. Can J Cardiol 2015; 31: 195 – 202.
dc.identifier.citedreferenceOreopoulos A, Padwal R, Kalantar‐Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: a meta‐analysis. Am Heart J 2008; 156: 13 – 22.
dc.identifier.citedreferencePonikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez‐Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891 – 975.
dc.identifier.citedreferenceYancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016; 68: 1476 – 1488.
dc.identifier.citedreferenceBhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016; 375: 65 – 74.
dc.identifier.citedreferencePitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383 – 1392.
dc.identifier.citedreferencePfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circulation 2015; 131: 34 – 42.
dc.identifier.citedreferenceRossignol P, Zannad F. Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west. Circulation 2015; 131: 7 – 10.
dc.identifier.citedreferenceFerreira JP, Girerd N, Rossignol P, Zannad F. Geographic differences in heart failure trials. Eur J Heart Fail 2015; 17: 893 – 905.
dc.identifier.citedreferencePocock S, Calvo G, Marrugat J, Prasad K, Tavazzi L, Wallentin L, Zannad F, Alonso Garcia A. International differences in treatment effect: do they really exist and why? Eur Heart J 2013; 34: 1846 – 1852.
dc.identifier.citedreferencePocock SJ, McMurray JJ, Collier TJ. Statistical controversies in reporting of clinical trials: Part 2 of a 4‐part series on statistics for clinical trials. J Am Coll Cardiol 2015; 66: 2648 – 2662.
dc.identifier.citedreferenceBristow MR, Enciso JS, Gersh BJ, Grady C, Rice MM, Singh S, Sopko G, Boineau R, Rosenberg Y, Greenberg BH. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC Basic Transl Sci 2016; 1: 180 – 189.
dc.identifier.citedreferenceGirerd N, Ferreira JP, Rossignol P, Zannad F. A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. Eur J Heart Fail 2016; 18: 1411 – 1414.
dc.identifier.citedreferenceShah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O’Meara, E Desai AS, Heitner JF, Li G, Fang J, Rouleau J, Zile MR, Markov V, Ryabov V, Reis G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail 2014; 7: 740 – 751.
dc.identifier.citedreferenceShah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, Pitt B, Pfeffer MA, Solomon SD. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation 2015; 132: 402 – 414.
dc.identifier.citedreferenceShah AM, Claggett B, Sweitzer NK, Shah SJ, Deswal A, Anand IS, Fleg JL, Pitt B, Pfeffer MA, Solomon SD. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circ Heart Fail 2015; 8: 1052 – 1058.
dc.identifier.citedreferencePandey A, Garg S, Matulevicius SA, Shah AM, Garg J, Drazner MH, Amin A, Berry JD, Marwick TH, Marso SP, de Lemos JA, Kumbhani DJ. Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: a meta‐analysis and systematic review. J Am Heart Assoc 2015; 4:e002137.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf814_am.pdf
Size:
437.4KB
Format:
PDF
View/Open
Name:
ejhf814.pdf
Size:
474.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.